Sparrow MP - Search Results

1

Is there a role for thioguanine therapy in IBD in 2017 and beyond?

Taylor KM, Ward MG, Blaker PA, Sparrow MP. Taylor KM, et al. Among authors: sparrow mp. Expert Rev Gastroenterol Hepatol. 2017 May;11(5):473-486. doi: 10.1080/17474124.2017.1294062. Epub 2017 Feb 20. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28276819 Review.

2

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.

Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Sparrow MP, et al. Clin Gastroenterol Hepatol. 2007 Feb;5(2):209-14. doi: 10.1016/j.cgh.2006.11.020. Clin Gastroenterol Hepatol. 2007. PMID: 17296529

3

Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.

Haines ML, Ajlouni Y, Irving PM, Sparrow MP, Rose R, Gearry RB, Gibson PR. Haines ML, et al. Among authors: sparrow mp. Inflamm Bowel Dis. 2011 Jun;17(6):1301-7. doi: 10.1002/ibd.21458. Epub 2010 Sep 1. Inflamm Bowel Dis. 2011. PMID: 20812329

4

Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence.

La Nauze RJ, Sparrow MP. La Nauze RJ, et al. Among authors: sparrow mp. Curr Drug Targets. 2011 Sep;12(10):1406-12. doi: 10.2174/138945011796818180. Curr Drug Targets. 2011. PMID: 21466496 Review.

5

Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.

Sparrow MP. Sparrow MP. Gastroenterol Hepatol (N Y). 2008 Jul;4(7):505-11. Gastroenterol Hepatol (N Y). 2008. PMID: 21960930 Free PMC article.

6

The role of thiopurine metabolite monitoring in inflammatory bowel disease.

Beswick L, Friedman AB, Sparrow MP. Beswick L, et al. Among authors: sparrow mp. Expert Rev Gastroenterol Hepatol. 2014 May;8(4):383-92. doi: 10.1586/17474124.2014.894878. Epub 2014 Mar 31. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24684593 Review.

7

Editorial: Escalation to weekly dosing in adalimumab-treated patients with active ulcerative colitis.

Ward MG, Sparrow MP. Ward MG, et al. Among authors: sparrow mp. Aliment Pharmacol Ther. 2014 Sep;40(6):730-1. doi: 10.1111/apt.12896. Aliment Pharmacol Ther. 2014. PMID: 25123387 Free article. No abstract available.

8

Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.

Taylor KM, Sparrow MP. Taylor KM, et al. Among authors: sparrow mp. Aliment Pharmacol Ther. 2015 Jul;42(1):119-20. doi: 10.1111/apt.13235. Aliment Pharmacol Ther. 2015. PMID: 26040520 Free article. No abstract available.

9

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.

Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA. Jones JL, et al. Clin Gastroenterol Hepatol. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8. doi: 10.1016/j.cgh.2015.06.034. Epub 2015 Jun 30. Clin Gastroenterol Hepatol. 2015. PMID: 26142167 Review.

10

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Ward MG, Irving PM, Sparrow MP. Ward MG, et al. Among authors: sparrow mp. World J Gastroenterol. 2015 Oct 28;21(40):11331-42. doi: 10.3748/wjg.v21.i40.11331. World J Gastroenterol. 2015. PMID: 26525434 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page